Global Anti-CD20 Monoclonal Antibodies (mAbs) Market Assessment, By Product Type [First Generation CD20 Monoclonal Antibodies, Second Generation CD20 Monoclonal Antibodies, Third Generation CD20 Monoclonal Antibodies], By Indication [Oncology, Neuroscienc

Global Anti-CD20 Monoclonal Antibodies (mAbs) Market Assessment, By Product Type [First Generation CD20 Monoclonal Antibodies, Second Generation CD20 Monoclonal Antibodies, Third Generation CD20 Monoclonal Antibodies], By Indication [Oncology, Neuroscience, Immunology, Others], By End-user [Hospitals, Specialty Clinics, Others], By Region, Opportunities and Forecast, 2017-2031F

Global anti-CD20 monoclonal antibodies (mAbs) market is projected to witness a CAGR of 9.84% during the forecast period 2024-2031, growing from USD 10.12 billion in 2023 to USD 21.44 billion in 2031. The market has experienced significant growth in recent years and is expected to maintain a strong pace of expansion in the coming years. The growth in the global anti-CD20 monoclonal antibodies (mAbs) market is driven by various factors such as the rising prevalence of autoimmune diseases, technological advancements, increasing investments in healthcare research, government initiatives, and reimbursement policies.

Growing private and public sector investments in the market, presence of several established players and strategies such as mergers and acquisitions, collaborations, and product launches are accelerating the global anti-CD20 monoclonal antibodies market growth. The global anti-CD20 mAbs market is further undergoing robust growth due to rise in prevalence of autoimmune diseases at global level. Anti-CD20 mAbs play a crucial role in the management of these autoimmune diseases. Anti-CD20 monoclonal antibodies are one of the most effective antibodies used in treatment of a wide range of diseases including cancer and immune related disorders. Other factors, such as improvements in healthcare facilities and technological advancements in the market, are further accelerating the growth of the global anti-CD20 mAbs market.

Government initiatives, favorable reimbursement policies, and growing awareness regarding the potential benefits of these antibodies in the proper management of auto-immune disease further encourage the use of these antibodies among the population. Due to these factors, several public and private companies invest in innovations, new products, and research and development of more efficient and effective anti-CD20 mAbs developments to provide quality medical treatment. Moreover, growing collaborations, mergers and acquisitions, and regulatory policies will further drive the growth of the global anti-CD20 monoclonal antibodies market.

In May 2023, Genmab A/S specialized in the development of differentiated antibody therapeutics to fight against cancer and other serious diseases announced that it received U.S. Food and Drug Administration (FDA) approval for EPKINLY (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

Increasing Prevalence of Autoimmune Diseases

The increasing prevalence of autoimmune diseases globally is a major driving factor for the global anti-CD20 mAbs market. Rheumatoid arthritis, systemic lupus erythematosus (lupus), inflammatory bowel disease (IBD), and multiple sclerosis are some of the most common autoimmune diseases. Both developed and developing countries are affected by immunological disorders. Global Autoimmune Institute stated that in 2022, 4% of the world’s population had at least one autoimmune disease. Autoimmune diseases are becoming more prevalent each year. Family history of autoimmune diseases, with at least one autoimmune disease, obesity, excessive tobacco consumption, and early exposure to certain infections are the leading risk factors for the rising prevalence of autoimmune diseases. Anti-CD20 mAbs such as Rituximab have shown tremendous potential in treating autoimmune diseases, due to which demand among the healthcare providers and patients is increasing. Growing awareness regarding the potential benefits of these antibodies in management of several diseases is driving the growth of the global anti-CD20 monoclonal antibodies market.

Technological Advancement in Anti-CD20 Monoclonal Antibodies (mAbs)

Anti-CD20 monoclonal antibodies have the potential to treat several autoimmune diseases and cancers. Due to its phenomenal success, there has been continuous development in the market, such as the development of first-generation CD20 monoclonal antibodies such as rituximab, second-generation CD20 monoclonal antibodies such as ocrelizumab, obinutuzumab, and veltuzumab and third generation CD20 monoclonal antibodies such as ocaratuzumab and PRO131921. In recent years, there has been a surge of innovative technologies aimed at overcoming the limitations of previous drugs, and we are in the process of bringing next-generation CD20 monoclonal antibodies into the market. These technological advancements increase the accuracy and efficiency of these drugs in treating diseases.

For instance, F. Hoffmann-La Roche Ltd. has numerous drugs in pipeline under clinical trials, waiting for FDA approvals, such as Gazyva/Gazyvaro (obinutuzumab), the first glycoengineered, type II, humanized anti-CD20 monoclonal antibody which is designed to selectively target the CD20 protein on B cells and to bind with high affinity to the cell surface in a type II configuration for the treatment of systemic lupus erythematosus (SLE) and lupus nephritis (LN).

Growing Demand for Anti-CD20 Monoclonal Antibodies in Immunology

Amongst the application category, immunology segment holds the maximum share in the global anti-CD20 monoclonal antibodies market. These antibodies have proved to be successful in treatment for various immunological disorders such as rheumatoid arthritis, multiple sclerosis, and systemic lupus erythematosus. Due to it, key market players are performing research and development and increasing investments in developing anti-CD20 monoclonal antibodies specially for managing these immunological disorders.

According to an article published in Journal of Neurology in October 2023, anti-CD20 monoclonal antibodies have huge success in treating multiple sclerosis, an immunological disorder. Anti-CD20 monoclonal antibodies such as rituximab, ofatumumab, ocrelizumab, and rituximab are the drugs that are either under clinical development or have been approved for the treatment of multiple sclerosis. Supportive regulatory systems enable pharmaceutical companies to invest in the research and development of these antibodies to improve their product portfolio, provide quality medical treatment, and accelerate market growth.

Hospitals Hold Dominant Share in the Market

Among the end-user segment, hospitals hold a significant market share in the global anti-CD20 monoclonal antibodies (mAbs) market. The rising prevalence of autoimmune disorders and the availability of advanced treatment methodologies are driving the demand for mAb therapy in hospitals. Anti-CD20 monoclonal antibodies are becoming popular among healthcare providers, therefore driving its adoption in specialty and multi-specialty hospitals. The use of anti-CD20 monoclonal antibodies has become standard practice in managing these conditions, contributing to improved patient outcomes and disease management. The ongoing development and clinical use of anti-CD20 monoclonal antibodies reflect their significant impact on modern healthcare and their potential for further advancements in treating various medical conditions.

North America Holds Largest Share in the Market

North America holds the highest share in the global anti-CD20 monoclonal antibodies market. The robust healthcare infrastructure of the region, along with high healthcare budgets and investments in providing improved healthcare facilities to the population involving innovative drug discoveries and manufacturing, and research and development in developing innovative, efficient drugs such as anti-CD20 monoclonal antibodies has led to the tremendous growth of the market in North America.

Moreover, the growing prevalence of autoimmune diseases in the United States and Canada has been a prominent factor in the region's huge demand for anti-CD20 monoclonal antibodies. According to Global Autoimmune Institute , in 2022, 8% of the United States population had at least one autoimmune disease. An increasing number of patients at a rapid scale is increasing demand for these potential anti-CD20 monoclonal antibodies such as Rituximab, Ofatumumab, and Obinutuzumab.

Future Market Scenario (2024 – 2031F)

Global anti-CD20 monoclonal antibodies market is expected to grow in the future, due to multiple factors. Primarily, the increasing prevalence of autoimmune diseases and cancer worldwide has increased the volume of anti-CD20 monoclonal antibodies in the healthcare industry. Increase in healthcare budgets, government initiatives, reimbursement policies, research and development, and innovative product launch by public and private bodies are further accelerating the growth of global anti-CD20 monoclonal antibodies market. Moreover, collaborative ventures involving biotech and pharmaceutical companies have spurred innovation and growth in the market.

Key Players Landscape and Outlook

In the anti-CD20 monoclonal antibodies market, public and private companies are progressively establishing initiatives, strategic partnerships, and distribution agreements, which are pivotal in driving the global anti-CD20 monoclonal antibodies market's expansion. These alliances empower firms to adapt to each other's strengths, gain access to new markets and technologies, and pool resources for research and development endeavors. Distribution agreements enable companies to broaden their market presence at an international level. These collaborative initiatives promote innovation, expedite product development and improved disease treatment, and contribute to the robust growth of the healthcare industry.

In December 2022, Biogen Inc. announced that it had signed an agreement with Genentech regarding glofitamab, an anti-CD20 monoclonal antibody. The strategic acquisition will enable Biogen Inc. to earn royalties on prospective net sales of glofitamab in the United States, which will not be subjected to any payment obligations under the terms of the agreement. It will help the company to improve its product portfolio for the management of several diseases and improve medical treatment. Moreover, the partnership aims to enhance in-depth knowledge, research and development activities, and launch new products in the market that will expand their global presence.